

"Express Mail" Label No. 332086417 US
Date of Deposit January 13, 2005

PATENT
Attorney Docket No.: 082398-000110US
Client Reference No.: E1-A0304P-US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

By: 
Aarón Hokamura

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

YOSHIKAWA et al.

Application No.: Not yet assigned

Filed:

U.S. National Phase of: PCT/JP03/07010

Int'l Filing Date: June 3, 2003

For: NOVEL CONDENSED
IMIDAZOLE DERIVATIVES

Examiner: Not yet assigned

Art Unit: Not yet assigned

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Kevin Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KLB:ath
60397651 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number		
			Filing Date		
			First Named Inventor	Yoshikawa, Seiji	
			Art Unit	Not yet assigned	
			Examiner Name	Not yet assigned	
Sheet	1	of	1	Attorney Docket Number	082398-000110US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AU	CLARK, Richard S. J. <i>et al.</i> ; "Novel piperazine-substituted, heterocyclic compounds as selective, competitive DPP-IV inhibitors"; <u>National Meeting & Exposition Program: 228th ACS National Meeting, Philadelphia, PA; August 22-26, 2004; Abstract 265; American Medical Society, ABSTRACT</u>	
	AV	CLARK, Richard S. J. <i>et al.</i> ; <u>Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan</u> , The 23rd Medicinal Chemistry Symposium, The 12th Annual Meeting of Division of Medicinal Chemistry (Tsukuba); November 24, 2004; Abstract 2P-11; Vol. 124, Suppl. 3.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.